matrix tablets.

The primary objective of this study is to investigate the potential of Lannea coromandelica gum (LCG) and Terminalia catappa gum (TCG) as agents to slow down the release of Vildagliptin in the development of once-daily matrix tablets. Both LCG and TCG are refined exudates obtained from their respective trees using established methods. To determine any interactions between the gums and the drug, Fourier transform infrared spectroscopy studies were conducted. Matrix tablets of Vildagliptin were created using these gums through the wet granulation technique. The granules were subjected to assessment for parameters such as angle of repose, bulk density, and compressibility index, which indicated favorable flow properties. The resulting tablets were then subjected to various quality control tests, including weight variation, hardness, and friability. All Vildagliptin matrix tablets exhibited uniform weight and drug content, with low standard deviation values. Dissolution studies confirmed that LCG and TCG can be employed as materials for forming the matrix in extended-release tablets. Kinetic release data analysis revealed that most of the solid matrix formulations conformed to Higuchi or zero-order kinetics.